IL22 and Hepatic fibrosis: In clinic studies, Xiang X et al. reported in chronic hepatitis B virus infected patients, IL-22 and non-ELR-CXC chemokines synergistically provided protection in liver inflammation and fibrosis [41], whereas other clinic studies revealed elevated systemic IL-22 were relevant with the progression of liver fibrosis [31, 52, 61].